Free Trial

OptimizeRx (OPRX) Stock Forecast & Price Target

OptimizeRx logo
$4.91 +0.16 (+3.37%)
(As of 12/20/2024 05:16 PM ET)

OptimizeRx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
6

Based on 8 Wall Street analysts who have issued ratings for OptimizeRx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, and 6 have given a buy rating for OPRX.

Consensus Price Target

$9.71
97.85% Upside
According to the 8 analysts' twelve-month price targets for OptimizeRx, the average price target is $9.71. The highest price target for OPRX is $18.50, while the lowest price target for OPRX is $5.00. The average price target represents a forecasted upside of 97.85% from the current price of $4.91.
Get the Latest News and Ratings for OPRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for OptimizeRx and its competitors.

Sign Up

OPRX Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
8 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.71$10.42$14.50$15.60
Forecasted Upside97.85% Upside113.89% Upside77.70% Upside11.43% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy

OPRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

OptimizeRx Stock vs. The Competition

TypeOptimizeRxComputer and Technology CompaniesS&P 500
Consensus Rating Score
2.75
2.69
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside97.85% Upside265.04% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent OPRX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/20/2024Stephens
4 of 5 stars
J. Garro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$5.50+15.79%
11/14/2024William Blair
2 of 5 stars
 Reiterated RatingOutperform
11/14/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$14.00 ➝ $7.00+75.44%
11/14/2024Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00+262.81%
11/14/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$13.00 ➝ $8.00+83.91%
11/14/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$11.00 ➝ $5.00-18.70%
How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now
11/14/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $8.00+30.08%
7/25/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$18.50+79.79%
8/15/2023Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$18.00 ➝ $13.00+3.42%
3/9/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Baldry
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
1/27/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:25 PM ET.


OPRX Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for OptimizeRx is $9.71, with a high forecast of $18.50 and a low forecast of $5.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OPRX shares.

According to analysts, OptimizeRx's stock has a predicted upside of 97.85% based on their 12-month stock forecasts.

OptimizeRx has been rated by research analysts at Barclays, JMP Securities, Roth Mkm, Royal Bank of Canada, Stephens, Stifel Nicolaus, and William Blair in the past 90 days.

Analysts like OptimizeRx more than other "computer and technology" companies. The consensus rating score for OptimizeRx is 2.75 while the average consensus rating score for "computer and technology" companies is 2.69. Learn more on how OPRX compares to other companies.


This page (NASDAQ:OPRX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners